



Published in final edited form as:

Alzheimers Dement. 2017 January ; 13(1): 8–19. doi:10.1016/j.jalz.2016.07.005.

The DIAN-TU Next Generation Alzheimer's prevention trial: adaptive design and disease progression model

Randall J. Bateman^{a,*}, Tammie L. Benzinger^a, Scott Berry^b, David B. Clifford^a, Cynthia Duggan^a, Anne M. Fagan^a, Kathleen Fanning^a, Martin R. Farlow^c, Jason Hassenstab^a, Eric M. McDade^a, Susan Mills^a, Katrina Paumier^a, Melanie Quintana^b, Stephen P. Salloway^d, Anna Santacruz^a, Lon S. Schneider^e, Guoqiao Wang^a, Chengjie Xiong^a, and the DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network

^(a)Departments of Neurology, Radiology and Biostatistics, Washington University in St. Louis, St. Louis, MO, USA

^(b)Berry Consultants, Austin, TX, USA

^(c)Indiana Alzheimer Disease Center, Indiana University, Indianapolis, IN, USA

^(d)Memory and Aging Program, Butler Hospital, Brown Medical School, Providence, RI, USA

^(e)Alzheimer's Disease Research Center, Keck School of Medicine of the University of Southern California, Los Angeles, CA, 90033 USA

Abstract

INTRODUCTION—The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) trial is an adaptive platform trial testing multiple drugs to slow or prevent the progression of Alzheimer's disease in autosomal dominant Alzheimer's disease (ADAD) families. With completion of enrollment of the first two drug arms, the DIAN-TU now plans to add new drugs to the platform, designated as the Next Generation Prevention Trial (NexGen).

METHODS—In collaboration with ADAD families, philanthropic organizations, academic leaders, the DIAN-TU Pharma Consortium, the NIH, and regulatory colleagues, the DIAN-TU developed innovative clinical study designs for the DIAN-TU NexGen trial.

RESULTS—Our expanded trials toolbox consists of a Disease Progression Model for ADAD, primary endpoint DIAN-TU cognitive performance composite, biomarker development, self-

*Corresponding Author, Randall J. Bateman, MD, Department of Neurology, Campus Box 8111, 660 South Euclid Avenue, St Louis MO 63110, 314.747.7066 office, 314.747.7060 fax, batemanr@wustl.edu.

Disclosure of Interests

AMF: Scientific advisory boards of IBL International and Roche; Consultant for DiamiR. RJB: Sources of Research Support: NIH R01NS065667, NIH U01AG032438 (DIAN), NIH U01AG042791 (DIAN-TU), NIH U01AG042791-S1 (DIAN-TU), NIH R1AG046179 (DIAN-TU-APT), Alzheimer's Association, BrightFocus Foundation, GHR Foundation, Anonymous Foundation, DIAN-TU Pharma Consortium: Amgen, AstraZeneca, Biogen, Eisai, Eli Lilly, Forum, Janssen AIP, Pfizer, Roche, Sanofi-Aventis; Companies: Co-founder C2N Diagnostics; Invited Speaker: Biogen, Fidelity Biosciences Research Initiative, EMA; Editorial Board: Alzheimer's Research and Therapy, The Journal of Prevention of Alzheimer's Disease; Consulting Relationships: Abbvie, Boehringer-Ingelheim, Forum (En Vivo) Scientific Advisory Board, Global Alzheimer's Platform.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

administered cognitive assessments, adaptive dose adjustments, and blinded data collection through the last participant completion.

CONCLUSION—These steps represent elements to improve efficacy of the adaptive platform trial and a continued effort to optimize prevention and treatment trials in ADAD.

Keywords

Alzheimer's disease; Alzheimer's Prevention Trial; Adaptive Clinical Trial; Biomarkers; Disease Progression Model; Cognitive Composite; Dose Adjustment; DIAN-TU; Amyloid; Tau; Autosomal Dominant Alzheimer's Disease

1. Introduction

Alzheimer's disease (AD) is a growing public and financial healthcare crisis. AD afflicts over 5 million people in the United States, with an expected increase to 13.8 million by the year 2050 (1). The costs for care of patients with AD and other dementias in 2015 was \$226 billion, which is predicted to increase beyond a trillion dollar annual cost by 2050 unless disease modifying treatments are developed. Because of the severity and increasing prevalence of the disease, better treatments and prevention are urgently needed.

Development of highly effective AD treatments has been hampered by the lack of surrogate biomarkers, slow course of cognitive and clinical decline, variability in clinical phenotype, and variability when measuring cognition and functional impairments in AD. These challenges are especially difficult since validated diagnosis of AD in the absence of symptoms has not yet been achieved. Prevention trials thus must be long and large due to inability to predict if and when cognitive symptoms will start, lack of functional impairment and difficulties identifying an at-risk study population prior to symptomatic cognitive decline.

In order to address key AD prevention trial design challenges in a population almost certain to develop AD – the autosomal dominant AD (ADAD) population – a public-private partnership was formed in 2010 to facilitate collaborative discussions between industry (the DIAN-TU Pharma Consortium, dian-tu.wustl.edu/en/pharma-consortium-members), ADAD families, the Alzheimer's Association, U.S. National Institute on Aging, regulators including FDA and EMA, and researchers (DIAN Observational Study, API, A4, CAP and others). Through these discussions, the DIAN-TU designed and executed a pioneering prevention trial for the ADAD population. The DIAN-TU Trial (DIAN-TU-001, www.clinicaltrials.gov) is also a public-private partnership supported by Eli Lilly, Roche, Alzheimer's Association, NIA, Avid Radiopharmaceuticals, GHR Foundation, Fidelity Biosciences Research Initiative, Cogstate and Bracket. Because the ADAD population is almost certain to develop cognitive impairment, at a younger and predictable age, several of the challenges inherent in conducting prevention trials of late-onset, sporadic AD are mitigated.

1.1 Autosomal Dominant Alzheimer's Disease

ADAD is caused by mutations in the *APP*, *PSEN1* or *PSEN2* genes, which lead to early-onset AD. Because of the almost certain risk of developing AD and the predictability of the

age at symptom onset (2, 3), ADAD represents a uniquely informative population for clinical trials. Unlike sporadic AD (SAD), the clinical onset of symptoms can be predicted throughout the lifespan, allowing drug trials to start years or even decades before symptoms occur (4). Potential therapeutic drugs were developed using cellular and animal models of identified ADAD mutations (5-8). These pre-clinical studies led to the development of agents used in anti-A β drug trials reaching clinical phase studies (9-15). While some remain in phase 3 trials, several have been discontinued due to adverse events (AEs) (16), worsened outcomes (17, 18), or lack of benefit (16, (19). Of concern, many of these trials failed to show target engagement of the proposed drug, largely due to lack of studies that adequately incorporated biomarkers (14, 15). Results from recent trials involving anti-A β antibodies (e.g. gantenerumab, crenezumab, solanezumab and aducanumab) have suggested that a greater magnitude of target engagement is critical and that treatment instituted earlier in the disease is possible and necessary for cognitive benefit (14, 20-23).

For families known to carry ADAD mutations, prevention and treatment trials using novel therapies offer the potential to delay or even prevent dementia in asymptomatic individuals and improve mild symptoms or mitigate symptom progression. Due to the younger age, higher capability of CNS repair, earlier stage of disease and A β as a likely initiator of ADAD, the ADAD population is expected to provide an efficient and, compared to sporadic AD, relatively rapid test for anti-A β therapeutics. The relative homogeneity of the DIAN-TU trial population, fewer comorbidities, low attrition to date, and the success in recruitment and completion of trial measures make the DIAN-TU trial and this patient population ideal for testing disease modifying therapies.

1.2 Relationship to Sporadic AD

Changes in cognitive, clinical, biochemical and structural measures in ADAD are similar to SAD (2, 24, 25). This suggests a common pathophysiology and provides rationale that treatment trials in ADAD are likely to provide insight into common treatments with the much more prevalent SAD. Prior studies of statins in familial hyperlipidemia (26) demonstrated a remarkable normalization of cholesterol deposits, which predicted improvements of lifespan by treatment of hypercholesterolemia in the general population by several decades (27). This is a historical precedent to what may be possible in ADAD and its relationship to SAD.

Three decades of accumulated research evidence supports the hypothesis that alterations in A β metabolism are necessary to cause AD (28, 29). In both SAD and ADAD, the presence of β -amyloidosis has been associated with cognitive decline in symptomatic individuals (30-32). In ADAD, cerebral amyloidosis correlates with worse baseline performance on multiple cognitive composites and predicts greater decline over time in global cognition, working memory, and Mini-Mental State Examination (MMSE) in symptomatic mutation carriers (32). Recent data from the DIAN observational study suggests that even in asymptomatic mutation carriers, the ratio of total tau to CSF A β_{1-42} is associated with longitudinal declines in episodic memory, language and global cognition (33). Similar results have been seen outside of ADAD populations, in which A β -positive healthy older adults show decline in episodic memory when compared with A β -negative healthy older

adults (30, 31). In contrast, an Icelandic mutation that reduces amyloidogenic processing of APP and also mildly decreases A β aggregation is protective against AD and age-related cognitive decline (34, 35). Together these data strengthen support for the amyloid hypothesis and the value of finding therapeutics targeting A β to treat both ADAD and SAD.

Regarding tau pathology, there is evidence in preclinical and clinical studies supporting a temporal relationship between A β plaque deposition and neurofibrillary tangles (NFT) development specifically in AD such that the development of A β plaques contributes the subsequent spread of NFT outside of the entorhinal cortex and hippocampus (36-38). In the aging process, NFTs can be seen starting in the 4th decade and appear to primarily develop in the entorhinal cortex and hippocampal areas (39) before the development of significant A β plaque. In the aging brain the spread of NFT pathology appears to be limited in the absence of coexisting A β pathology (40-42). Based on autopsy series of patients, the distribution of NFT pathology appears similar between ADAD and SAD (43). Further, recent studies in the DIAN have demonstrated similar distributions of tau PET signals in ADAD and SAD (44). Thus, the distribution and type of tau pathology among ADAD and SAD are analogous. Ongoing studies will clarify the role of aging in NFT development and further characterize tau pathology associated with cognitive and clinical impairment.

In SAD a dynamic sequence of biomarker changes has been proposed (24, 45) with cerebral amyloidosis being one of the first detectable changes, followed by measures of neurodegeneration and lastly cognitive and functional decline. Longitudinal and cross-sectional studies in ADAD (4, 46, 47) have supported the same relationship. Although further studies are required in both populations, the temporal order and progression of pathophysiological, cognitive and clinical changes are shared in ADAD and SAD (3).

2. The DIAN-TU Alzheimer's Disease Prevention Trial Platform

The DIAN-TU platform (NCT01760005; See Figure 1) was launched to accelerate identification of effective drugs for prevention and treatment of ADAD (48, 49). In 2012, a phase 2/3 double-blind, randomized, pooled-placebo controlled two-year biomarker trial began by testing two drugs – solanezumab (an anti-soluble A β antibody) and gantenerumab (an anti-fibrillar A β antibody). The study transitioned within the DIAN-TU platform to the Adaptive Prevention Trial in 2014 as a four-year Phase 3 cognitive endpoint trial to determine whether A β antibody administration demonstrating central nervous system (CNS) biomarker target engagement is able to prevent cognitive decline in cognitively normal individuals. The DIAN-TU trial is now operational in 7 countries (Australia, Canada, France, Italy, Spain, UK and US), 26 sites, and 4 languages (English, French, Italian and Spanish) (See Figure 2). Full enrollment of the first two drug arms has been achieved with a high assessment completion rate and low attrition. The DIAN-TU trial is one of five ongoing trials aiming to prevent or delay the onset and progression of AD (50).

2.1 DIAN-TU Next Generation

As enrollment for the first two arms was completed in late 2015, the DIAN-TU is preparing to launch two new drug arms as the Next Generation (NexGen) Prevention Trial (see Figure 1). The NexGen trial will be a multi-center, double blind, randomized, pooled-placebo

controlled, four-year cognitive composite endpoint registration study of two potential disease modifying therapies in 160 mutation carriers at risk for or with mild symptomatic ADAD. The NexGen trial proposes to test the ability of a beta secretase inhibitor (BACEi), gamma-secretase modulator, and other novel A β or tau-based therapies to slow or prevent cognitive decline in asymptomatic (CDR 0) to mildly symptomatic (CDR 0.5 or 1) ADAD mutation carriers in the range of -15 to +10 years with respect to estimated years to symptom onset (EYO). The DIAN-TU anticipates future development of AD specific pathophysiology interventions which may include combination treatments. Each drug program will include at least 80 mutation carrier subjects who receive either drug or placebo randomized 3:1. Cognitive benefit will be determined over 4 plus years with the primary outcome being the DIAN-TU cognitive composite and secondary outcomes including multiple cognitive and clinical measures and cerebrospinal fluid and imaging biomarkers.

The NexGen trial goals are to enable rapid testing of novel approaches, inform if dementia can be prevented or delayed in ADAD subjects, provide publicly accessible data and biological samples for research, and develop surrogate biomarkers to accelerate future AD trials. NexGen working groups evaluated additional designs that allow the platform to test drugs with diverse mechanisms of action more quickly. Significant innovations that may be implemented include: an ADAD Disease Progression Model (DPM) to detect changes in cognition with fewer participants compared to traditional Mixed Effects Model for Repeated Measures (MMRM), self-administered cognitive testing, a pre-defined dose escalation algorithm to safely maximize target engagement, adaptive trial design that includes both early biomarker and later cognitive interim analyses to inform early efficacy or futility, and novel imaging (e.g. Tau PET and diffusion basis spectrum imaging MRI).

3. Methods and Results

3.1 Primary Endpoint – DIAN-TU Cognitive Composite

Utilizing the latest DIAN observational data limited to participants meeting DIAN-TU trial eligibility criteria, we developed a cognitive composite using sensitive and reliable tests that together represent cognitive domains affected in AD – particularly in the very early stages – including episodic memory, executive functioning, processing speed, and mental status. The DIAN-TU cognitive composite consists of the delayed recall score from the International Shopping List Test, the Logical Memory delayed recall score from the Wechsler Memory Scale-Revised, the Digit Symbol Coding test total score from the Wechsler Adult Intelligence Scale-Revised, and the MMSE total score. These measures were selected based on their psychometric characteristics (reduced ceiling and floor effects, relatively low variability), sensitivity to subtle declines prior to clinical diagnosis, and face-validity as indicators of the cognitive phenotype of AD. Since the DIAN-TU is a multi-site international study, translations were necessary. Translation of the test stimuli for the International Shopping List Test followed procedures described in Lim and colleagues (2012)(51), which selects stimulus words representing commonly available items in the language and culture of interest. A similar procedure was followed for translation of the paragraph used in the WMS-R Logical Memory test, wherein translations represent an adaptation of the content rather than a word-by-word translation (Acevedo et al., 2012) (52).

This process relies on multiple reviews and revisions during translations with native speakers with the ultimate goal of achieving conceptual and cross-cultural equivalence. Power analyses indicate the DIAN-TU composite is sensitive to decline and produces feasible sample size requirements to detect prescribed effect sizes.

We have vetted our composite by taking advantage of the longitudinal database from the DIAN observational study cohort (See Figure 3). These analyses have shown that the proposed DIAN-TU Cognitive Composite can detect declines up to 10 years prior to estimated age of symptom onset. The composite has good distributional characteristics across the trial range of EYO and good separation of mutation carriers and non-carriers years prior to symptom onset. The DIAN-TU Cognitive Composite is a valid indicator of the cognitive phenotype of AD and is directly comparable to cognitive endpoints of other secondary prevention clinical trials in AD, thus allowing future comparisons of clinical trial outcomes between ADAD and SAD. For example, the Anti-Amyloid in Asymptomatic Alzheimer's disease (A4) trial has chosen an endpoint that includes measures of episodic memory (verbal list learning [Free and Cued Selective Reminding Test] and paragraph recall [Logical Memory]), complex attention (Digit Symbol Coding) and a general cognitive screen (MMSE) (21).

3.2 Primary Analysis – ADAD Disease Progression Model

Traditional trial designs in AD have focused on comparing the absolute change from baseline in a cognitive measure at a fixed time post randomization. This creates considerable variability because patients vary in their stage of disease at study entry and in their rates of decline. Historically, staging disease in sporadic AD populations has been challenging due to heterogeneity at baseline and in the longitudinal trajectories of patients enrolled in therapeutic trials. Additionally, analyses focused on absolute changes at a pre-defined time point only weakly incorporate the longitudinal changes in progression. This results in trials with low power to demonstrate clinically important effects and increases the likelihood of type II error. Moreover, while clinically significant change may be clearly measurable in mild-moderate AD, preclinical or very mild stages will require mechanisms to detect small changes in outcomes that have meaningful downstream impacts.

The DIAN observational study has identified highly predictable and consistent changes that occur decades before onset of clinical symptoms (4), and we have used this valuable information to create a DPM that dramatically improves our ability to detect drug effects in DIAN-TU trials. In subjects who are not yet symptomatic, we can estimate accurately and reliably the number of years until symptom onset (3). With longitudinal follow up we are continuously able to gather a more comprehensive understanding of the rate of cognitive decline across the spectrum of EYO and how these declines manifest across different cognitive domains. One important finding from the analyses of the longitudinal data from the DIAN observational study is that the disease progression in the cognitive composite in mutation carriers is non-linear (Figure 4, left panel). Therefore, we have developed a cognitive endpoint non-linear mixed effects model with EYO as the measure of time for each subject, not time from randomization (manuscript in preparation). The model estimates the expected rate of cognitive decline for untreated mutation carriers. By incorporating two

important random effects for each individual – a subject's EYO and a subject's baseline cognitive performance – the rate of decline becomes more homogeneous and with much less variability (Figure 4, right panel). Within this disease progression model we develop a *proportional* disease modification parameter for treatments relative to placebo subjects. This parameter is identified more precisely by the entire longitudinal data for treated and placebo subjects.

While we assume that the expected proportion of the change in the cognitive measure under a treatment relative to placebo is constant across EYO, the expected absolute difference in the cognitive readout for drug treatment relative to placebo will vary depending on the EYO of the subject and the duration of treatment. Figure 5 provides an illustration of hypothetical proportional changes to the disease progression and the gradual increase in the absolute effect for a range of EYO entry points based on a treatment effect over the four-year duration of the trial. The percent slowing of the progression rate in Figure 5 ranges from 0-70% encompassing reported cognitive and clinical effects of A β immunotherapies; 34% reduction in cognitive decline for solanezumab (22) and 66%-75% reduction in MMSE and CDR for aducanumab (21). Importantly, the estimated standard deviation of a single visit in the DIAN-TU cognitive composite is 0.33 (Estimate of the disease progression model fit to the observational cohort from data freeze 9). Thus, a change in the DIAN-TU cognitive composite over time of 0.25 creates a statistical “effect” size of $0.25/0.33 = 0.756$. For a 1-unit change in the cognitive composite this corresponds to a statistical effect size of $1.0/0.33 = 3$. Thus, effect sizes of 0.756 for asymptomatic and 3 for symptomatic are quite large in the DIAN population. For a drug which causes 50% slowing of the rate of decline, treatment effect sizes of $0.756/2 = 0.378$ and $3/2 = 1.5$ are statistically achievable with sample sizes from 80 to 140 subjects with 4 plus years of follow-up.

Importantly, the DPM provides for very high power to determine whether a treatment slows the rate of decline in a randomized trial. The DPM shows dramatically increased power compared to a mixed model for repeated measures (MMRM), that has weak measures of the treatment effect over time and a weak allowance for capturing the influential covariate, EYO. For example, with 60 mutation carrier treatment subjects and 40 mutation carrier placebo participants enrolled, the power to determine superiority when there is a 30% slowing of disease progression, is 0.24 for the MMRM and 0.90 for the proposed DPM. Additionally, the precision of this model allows more timely decisions of superiority and futility for treatments with clear benefit or minimal to no benefit.

3.3 DIAN-TU NexGen Secondary Outcome Measures

A wide range of secondary analyses will be conducted, including efficacy analysis using MMRM to compare to the DPM and analyses of additional individual cognitive and clinical tests. Modeling for both the primary and secondary analyses will adjust for well-established risk factors and covariates such as baseline age, *APOE4* status, education and gene mutation type. Analyses will be done on functional measures of activities of daily living, all biomarker measures (e.g. CSF A β_{1-40} , A β_{1-42} , tau and p-tau181, regional amyloid PET, volumetric MRI, and Tau PET), and on the incidence of CDR conversion from baseline.

3.3.1 Exploratory Self-Administered Internet-Based Cognitive Assessments—

It is expected that the reliability of the observations of the subtle changes over time increases with the number of measurements used to estimate that change. An exploratory aim for secondary analysis in the NexGen trial will be to introduce self-administered brief cognitive assessments using a validated Internet-based testing portal. The self-administered battery will include the computerized measures that comprise the 12-minute Cogstate Brief Battery, which is a component of the larger cognitive assessment battery currently in use in DIAN-TU. The overall goal is to collect more frequent cognitive assessments to test the hypothesis that this will increase reliability of the measurement of subtle cognitive change without substantially increasing study costs and burden for DIAN-TU participants. To our knowledge, this is the first trial design to incorporate self-administered assessments in a clinical trial investigating an AD disease-modifying agent.

3.3.2 Biomarker Effects of DIAN-TU Trial Drugs—Convergence and consensus in the field has generated significant support for biomarkers in AD prevention trials (2, 53). The DIAN observational study was established as the first international registry and longitudinal study of ADAD to determine the temporal course of biomarker changes relative to AD symptom onset as well as to support clinical trials in this largely asymptomatic population. Discovery and validation of AD biomarkers for identifying individuals most likely to respond to treatments, measuring responses to treatments, and predicting clinical benefit of treatments (surrogate biomarkers), are a high priority to increase the efficiency of trials for AD.

3.3.2.1 Tracking Target Engagement: Drugs are developed to target pathological proteins and processes (e.g. increased A β production and/or deposition), and the efficacy with which they engage the target can be assessed with biomarkers. The DIAN-TU NexGen trial is testing two drugs in parallel to assess target engagement using primary biomarker readouts including amyloid PET imaging for anti-A β antibodies and CSF A β ₁₋₄₀ and A β ₁₋₄₂ for BACE inhibitors.

3.3.2.2 Finding a Surrogate Biomarker for AD Clinical Trials: From inception, the DIAN-TU trial has assessed many biomarkers. Should a drug demonstrate cognitive benefit it will be possible to analyze which biomarkers best predicted therapeutic efficacy, findings of particular benefit for future AD trials. The need for predictive biomarkers is especially important in slowly progressive disorders like AD, without which prevention trials will necessarily be large, long, and expensive (54). The inclusion of multiple biomarkers will allow for the analysis of multiple potential responses to therapies and also better reflect the array of biomarker used to predict progression from the observational study.

As there is not yet an established predictive biomarker for AD, we have included a diverse panel of imaging and fluid AD biomarkers to determine drugs' impact on different aspects of the pathobiology including atrophy (MRI), connectivity (functional MRI), metabolism (FDG PET), amyloid pathology (amyloid PET), tau pathology (tau PET), vascular factors (MRI white matter), and biochemical changes (CSF). Novel CSF markers of synaptic dysfunction and neurodegeneration, imaging markers including tau PET and MRI diffusion sequences to better understand Amyloid Related Imaging Abnormalities (ARIA) will be

implemented. Exploratory biofluid and imaging analyses include measurement of CSF tau, ptau, VILIP-1 (visinin-like protein 1, neuronal injury/degeneration) (55) and NGRN (neurogranin, [post-] synaptic dysfunction) (56-58). Potential future exploratory biomarkers evaluated independently at trial completion include CSF synaptosomal-associated protein-25 (SNAP-25, [pre-] synaptic dysfunction) (59) and neurofilament light chain (NfL, axonal injury) (60) and plasma tau (neuronal injury/ degeneration) (61).

In particular, inclusion of tau PET imaging for the DIAN-TU NexGen drug arms will significantly enhance the trial and provide an opportunity to maximize understanding of the role of tau in AD. Inflection of CSF tau appears to predict the clinically critical cognitive decline in AD. Quantification of aggregated brain tau will be used as a secondary outcome measure to: determine whether therapeutics lowering amyloid in pre-symptomatic and mild AD can decrease insoluble brain tau levels and whether treatment timing influences the outcome; quantify the rate of aggregated brain tau changes in placebo treated ADAD participants in various stages of disease; test the hypothesis that aggregated tau levels can predict progression from asymptomatic to symptomatic AD; and analyze tau PET dynamics in the context of other imaging and CSF biomarkers in mutation carriers and non-carriers.

3.3.2.3 Biomarker Analyses and Understanding Adverse Events: Extensive characterization of DIAN-TU participants may also elucidate mechanisms of amyloid related imaging abnormalities (ARIA) that have been increased in frequency by some amyloid therapeutics. The DIAN observational cohort has demonstrated normal brain MRIs until the time of transition to symptomatic AD, at which point atrophy, white matter disease, and microhemorrhages (MHE) begin to manifest (62). Prevalence of MHE in the DIAN observational cohort is 15% overall with only 2.9% having greater than one MHE. The lack of other age and disease related comorbidities that are risk factors for MHE in the DIAN population allows us to characterize ARIA related to AD and to drug effects. To do so in greater detail, we will employ diffusion basis spectrum imaging (DBSI), a novel form of DTI analysis, permitting separation of free water (edema) from cellular infiltrate more consistent with possible inflammatory processes (63, 64).

3.3.2.4 A Community Resource: As the DIAN-TU trial is a public-private partnership with funding from the NIH, data and samples will serve as a resource for researchers. The trial will generate a repository of CSF and blood samples, imaging data and biomarker results providing a resource for qualified investigators to help develop novel and better-validated AD clinical trial biomarkers.

3.4 Dose Adjustment Algorithm

As a critical component of the adaptive platform trial design, combined safety/biomarker-target analyses at years one and two will enable dosing decisions to maximize biomarker target engagement. Although dose optimization is conventionally performed during phase I/II studies, we propose an opportunity for dose adjustment in DIAN-TU NexGen for multiple reasons. First, doses identified in phase I/II studies of amyloid specific agents have not consistently translated to target engagement and efficacy in larger, later phase studies (23, 65). Second, with early evidence of biomarker target engagement we ensure that

decisions are made quickly and thereby avoid the mistake of identifying a sub-therapeutic dose after four years, preventing the loss of precious time and resources. Third, the current DIAN-TU population has had few drug-related AEs indicating higher doses may be tolerated in this younger population. By starting with or progressing to higher doses in NexGen and then performing an early safety/biomarker analysis at year one, we will be well positioned to assess the appropriate dose in the ADAD population.

A dose escalation algorithm would account for safety signals and biomarker target engagement at interim analyses of both NexGen drugs, with precise cutoffs and safety profiles tailored to each compound based on preclinical and clinical data. After one year of drug and placebo exposure, a drug not meeting a minimal acceptable change in CSF A β or decrease in amyloid PET accumulation compared to baseline may be offered an opportunity to increase dose (provided there is also an acceptable safety profile). A clinical safety and biomarker interim analysis by an unblinded team will determine whether drug dosage should increase, decrease, continue at current dose, or be dropped due to futility of low biomarker engagement.

3.5 Interim Analyses

Due to significant power gains from the ADAD DPM, it may be possible to declare early success in the NexGen trial. Thus, interim analyses of cognitive outcomes are proposed when the last enrolled participant in a treatment cohort reaches two years and three years of follow-up. At each interim a regimen may be stopped for futility if the experimental therapy demonstrates a lack of efficacy (probability of at least a 20% slowing of cognitive decline is less than 5%) or stopped early due to demonstration of cognitive efficacy (the primary analysis using only the interim data showing statistically superior slowing of progression). If neither of these decisions is reached then the regimen will continue to the next interim analysis or the final analysis when the last participant has completed four years of treatment. A detailed stopping boundary for the interim efficacy analyses will be developed.

Biomarker interim analysis at year one will examine change from baseline for a drug's primary biomarker of target engagement. For drug programs that have a dose escalation at year one, a year two evaluation of safety and biomarker engagement will be performed similar to year one. However, dose-escalated drug programs that still have not safely demonstrated high impact on their biomarker of CNS target engagement at year two will be discontinued.

3.6 Extended Randomized Follow-up

Due to the extended periods of monitoring needed for cognitive change in prevention trials, any additional data on cognitive changes due to drug effects are highly valuable in determining the potential for drugs to slow or delay cognitive loss. We simulated collecting and analyzing all randomized data collected in the DIAN-TU trial from first patient in to last patient visit by having all participants continue randomized treatment until trial completion. Depending on the assumptions of trial enrollment duration and effect size, various improvements in power ranged from 1% to 30%. For example, a trial with a drug showing 30% slowing of disease progression (60 active to 40 placebo in mutation carrier subjects)

has a 60% chance of demonstrating efficacy with exactly four years of follow-up, whereas the same scenario allowing randomized participants to continue until the last subject reaches four years has 90% power. The valuable data collected beyond the four-year point provides highly informative measures to better estimate drug effects. These improvements in power take no additional time for the trial, and can be implemented with modest costs of follow-up.

3.7 NexGen Drug Candidates and Combination Therapy

Diversifying the drug portfolio has been a longstanding DIAN-TU trial platform goal to increase the likelihood of finding an effective therapy and mitigating the inherent risk of individual drug failure due to unpredicted toxicity, lack of availability or lack of efficacy. Two therapeutics will be chosen from the DIAN-TU Therapy Evaluation Committee imminent use category and are likely to include a class to target A β production. Future therapeutics tested in the DIAN-TU platform may include tau-based treatments and other non-A β targets.

An original goal of NexGen trial design included testing of combination therapy to delay onset and progression of AD. Preclinical data suggest combining therapeutics targeting the amyloid cascade (anti-A β and BACEi) significantly enhances reduction of amyloid load and plaque number beyond either monotherapy alone (66, 67). The existing and NexGen arms will be testing individual therapeutics that are a possible first combination (68-71), and the DIAN-TU trial platform's multiple monotherapies and pooled placebo allow an opportunity to test combinations alongside monotherapy. Moreover, the platform provides a unique opportunity for companies to work together minimizing complicated licensing and contracts. However, as yet there has been no disease modifying combination nominated for consideration by the DIAN-TU Therapy Evaluation Committee. Thus, combination therapy remains a desirable future aim of the DIAN-TU platform.

3.8 Engaging ADAD Participants

There is a growing movement to include patient-centered outcomes in the drug development process. The DIAN-TU uses surveys (72), webinars and an annual ADAD Family Conference (<http://dian-tu.wustl.edu/en/adad-family-conference>) to gather feedback on trial design and risk tolerance in the ADAD community. Pooled placebo and ability of individuals with undisclosed mutation status to participate in the trial – two central features of the original trial design – were incorporated as a direct result of patient engagement. Pooling data across placebo subjects from different drug arms provides participants with a 75% chance of receiving active drug rather than 50% in traditional 1:1 randomization. However, pooled placebo requires special attention to issues of equivalence and comparability. For example, sensitivity analyses are used to confirm that placebo groups across arms can be combined for the purpose of pooled placebo analyses. Further operational similarities across arms in the DIAN-TU trial support similarity in enrollment, assessments, and duration of the study. Inspired by ADAD families, the DIAN-TU NexGen design aims to test more drugs more quickly by decreasing required participant number using the ADAD DPM, declaring futility or success earlier, and maximizing dose and effect size via the dose adjustment algorithm.

Because ADAD is a rare disease, we have implemented multiple outreach strategies to recruit and engage eligible participants through the DIAN observational study, DIAN Expanded Registry (DIAN EXR) and referrals from partnering clinicians and sites with over 3500 potential participants identified. The DIAN-TU EXR offers exploratory genetic counseling and exome sequencing for families with early onset AD but without confirmation of an ADAD mutation. It is possible that through the EXR, meaningful information such as remote cognitive testing could be captured. Similar programs such as the Brain Health Registry, www.brainhealthregistry.org, are underway in the aging population. However, no such registry exists in ADAD. Additionally, with the platform design of the DIAN-TU trial there will be times enrollment is on hold. During these periods the EXR could continue to capture cognitive assessments and other data that might be helpful at the start of new drug arms such as those proposed in the NexGen trial.

4. Discussion

A therapy delaying the onset of AD dementia by five years that is introduced by 2025 would reduce the number of expected cases by 42% by 2050 and save the United States \$367 billion annually on costs of care (73). While a treatment advance in the ADAD population would have to be tested in sporadic AD, we believe the data supports that DIAN-TU trial outcomes may be utilized as supportive or as one of two pivotal trials to demonstrate effectiveness in sporadic AD. A full evaluation of the comparability between ADAD and sporadic AD is underway with large ongoing observational studies in ADNI, NACC and DIAN, which will help inform about the translatability between ADAD and sporadic AD.

In support of the U.S. National Alzheimer's Project Act plan of finding an effective disease modifying therapy by 2025, the DIAN-TU NexGen trial design was developed through collaborations with DIAN-TU NexGen and Pharma Consortium members, DIAN and DIAN-TU subjects, patient groups (Alzheimer's Association and ADAD Family Forum), academic, clinical trial and statistics experts. Central themes emerged including a focus on the adaptive trial platform to minimize cycle time, ensure maximal learning from the limited population of ADAD participants and increase the chance of finding a treatment that provides cognitive benefit. The trial becomes stronger as more regimens are added, and regular interims with more stringent definitions of failure and success allow faster decision-making. Substantial power gains are achieved by using the disease progression model. The NexGen trial aims for a larger effect size by employing a drug-specific dose escalation algorithm to maximize target engagement, biomarker changes and cognitive benefit over time. Finally, the trial will provide additional value to the Alzheimer's field by investigating a comprehensive array of fluid and imaging biomarkers and cognitive tests. Inherent limitations include the possibility of small effects in a small sample size and as yet no clear relationship between biomarker changes and clinical efficacy.

The DIAN-TU NexGen trial will benefit from time and cost saving efficiencies established by the existing DIAN-TU platform operations and infrastructure. We have accounted for the common risks of choosing a single unproven drug in a long-term prevention trial, subject enrollment and retention, selection of cognitive outcomes, and power to detect a clinically

significant drug effect. If the DIAN-TU trial successfully identifies an effective therapeutic or surrogate biomarker, the impact on patients, societies and economies may be substantial.

Acknowledgements

The NexGen trial design work was supported by Fidelity Biosciences Research Initiative, the Alzheimer's Association, GHR Foundation, and the DIAN-TU Pharma Consortium. The DIAN-TU trial is supported by the Alzheimer's Association, Eli Lilly, Roche, NIH U01AG042791, NIH U01AG042791-S1, NIH R1AG046179, Avid Radiopharmaceuticals, Cogstate, Bracket and GHR Foundation. Data collection and sharing for this project was supported by The Dominantly Inherited Alzheimer Network (DIAN, U19AG032438) funded by the National Institute on Aging (NIA) and the German Center for Neurodegenerative Diseases (DZNE). This manuscript has been reviewed by DIAN Study investigators for scientific content and consistency of data interpretation with previous DIAN Study publications. We acknowledge the altruism of the participants and their families and contributions of the DIAN and DIAN-TU research and support staff at each of the participating sites for their contributions to this study. The authors would also like to thank Jacki Mallmann and Amanda Fulbright for technical and administrative assistance.

References

1. Brookmeyer R, Evans DA, Hebert L, Langa KM, Heeringa SG, Plassman BL, Kukull WA. National estimates of the prevalence of Alzheimer's disease in the United States. *Alzheimers Dement*. 2011; 7(1):61–73. PubMed PMID: 21255744; PMCID: 3052294. DOI: 10.1016/j.jalz.2010.11.007 [PubMed: 21255744]
2. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. *Alzheimer's research & therapy*. 2011; 3(1):1. Epub 2011/01/08. PubMed PMID: 21211070; PMCID: 3109410. doi: 10.1186/alzrt59
3. Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, Lopera F, Martins R, Masters CL, Mayeux RP, McDade E, Moreno S, Reiman EM, Ringman JM, Salloway S, Schofield PR, Sperling R, Tariot PN, Xiong C, Morris JC, Bateman RJ, Network DIA. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. *Neurology*. 2014; 83(3):253–60. PubMed PMID: 24928124; PMCID: PMC4117367. DOI: 10.1212/WNL.0000000000000596 [PubMed: 24928124]
4. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC. Dominantly Inherited Alzheimer N. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med*. 2012; 367(9):795–804. PubMed PMID: 22784036; PMCID: 3474597. DOI: 10.1056/NEJMoa1202753 [PubMed: 22784036]
5. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. *Nature*. 1999; 400(6740):173–7. PubMed PMID: 10408445. DOI: 10.1038/22124 [PubMed: 10408445]
6. Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Desai R, Hancock WW, Weiner HL, Selkoe DJ. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. *Annals of the New York Academy of Sciences*. 2000; 920:328–31. PubMed PMID: 11193172. [PubMed: 11193172]
7. Chang WP, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM, Ghosh AK, Tang J. Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2011; 25(2):775–84. PubMed PMID: 21059748; PMCID: 3023390. DOI: 10.1096/fj.10-167213 [PubMed: 21059748]
8. Qu BX, Xiang Q, Li L, Johnston SA, Hynan LS, Rosenberg RN. Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. *Journal of the neurological sciences*. 2007;

260(1-2):204–13. PubMed PMID: 17574274; PMCID: 2587214. DOI: 10.1016/j.jns.2007.05.012 [PubMed: 17574274]

9. Sperling R, Salloway S, Raskind M, Ferris S, Liu E, Yuen E, Lu Y, Wang D, Nejadnik B, Guenzler V, Grundman M, Black R, Brashear R. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineusumab in patients with mild to moderate Alzheimer's disease who are apolipoprotein E ϵ 4 carriers. Top-line clinical and biomarker results for carriers. Presented at the 16th Congress of the European Federation of Neurological Societies. *Eur J Neurol.* 2012; 19
10. Sperling, R.; Salloway, S.; Raskind, M.; Ferris, S.; Honig, L.; Porsteinsson, A.; Sabbagh, M.; Liu, E.; Miloslavsky, M.; Reichert, M.; Ketter, N.; Lu, Y.; Wang, D.; Nejadnik, B.; Grundman, M.; Black, R.; Brashear, R., editors. Bapineuzumab Phase 3 trials in mild to moderate Alzheimer's disease dementia in apolipoprotein ϵ 4 carriers (Study 302) and non-carriers (Study 301). Top-line clinical and biomarker results for carriers, non-carriers, pooled studies, and mild and moderate groups. Oral presentation. 137th American Neurological Association Annual Meeting October 7-9, 2012; Boston, MA. 2012; ANA;
11. Dodel RC, Hampel H, Du Y. Immunotherapy for Alzheimer's disease. *Lancet Neurol.* 2003; 2(4): 215–20. PubMed PMID: 12849209. [PubMed: 12849209]
12. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. *Lancet Neurol.* 2010; 9(4):363–72. PubMed PMID: 20189881. DOI: 10.1016/S1474-4422(10)70043-0 [PubMed: 20189881]
13. Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, May PC. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. *Clinical neuropharmacology.* 2007; 30(6):317–25. PubMed PMID: 18090456. DOI: 10.1097/WNF.0b013e31805b7660 [PubMed: 18090456]
14. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. *N Engl J Med.* 2014; 370(4):311–21. Epub 2014/01/24. PubMed PMID: 24450890. DOI: 10.1056/NEJMoa1312889 [PubMed: 24450890]
15. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR, Investigators BaCT. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. *N Engl J Med.* 2014; 370(4):322–33. PubMed PMID: 24450891; PMCID: PMC4159618. DOI: 10.1056/NEJMoa1304839 [PubMed: 24450891]
16. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. *Neurology.* 2003; 61(1):46–54. PubMed PMID: 12847155. [PubMed: 12847155]
17. Panza F, Frisardi V, Imbimbo BP, Seripa D, Solfrizzi V, Pilotto A. Monoclonal antibodies against beta-amyloid (A β) for the treatment of Alzheimer's disease: the A β target at a crossroads. Expert opinion on biological therapy. 2011; 11(6):679–86. PubMed PMID: 21501112. DOI: 10.1517/14712598.2011.579099 [PubMed: 21501112]
18. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS, Siemers E, Sethuraman G, Mohs R. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. *N Engl J Med.* 2013; 369(4):341–50. Epub 2013/07/26. PubMed PMID: 23883379. DOI: 10.1056/NEJMoa1210951 [PubMed: 23883379]
19. Vellas B. Tarenflurbil for Alzheimer's disease: a "shot on goal" that missed. *Lancet Neurol.* 2010; 9(3):235–7. DOI: 10.1016/S1474-4422(10)70030-2 [PubMed: 20170836]
20. Salloway S, Sperling R, Honig L, Porsteinsson A, Sabbagh M, Liu E, Yuen E, Lull J, Miloslavsky M, Reichert M, Ketter N, Grundman M, Black R, Brashear R. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineusumab in patients with mild to moderate Alzheimer's disease who are apolipoprotein E ϵ 4 non-carriers. Top-line clinical and biomarker

results for non-carriers. Presented at the 16th Congress of the European Federation of Neurological Societies. Eur J Neurol. 2012; 19

21. Strobel, G. Biogen Antibody Buoyed by Phase 1 Data and Hungry Investors. International Conference on Alzheimer's and Parkinson's 2015 [Internet]; 2015; Part 1 of 10: B. Available from: <http://www.alzforum.org/news/conference-coverage/biogen-antibody-buoyed-phase-1-data-and-hungry-investors>
22. Siemers, ELS.; H.; Aisen, PS.; Andersen, SW.; Holdridge, KD., editors. Delayed-start analyses of up to 3.5 years in phase 3 solanezumab expedition program in mild Alzheimer's disease. Alzheimer's Association International Conference 2015; Washington, DC.
23. Strobel, G. Aducanumab, Solanezumab, Gantenerumab Data Lift Crenezumab. As Well2015;AlzForum
24. Jack CR Jr. Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010; 9(1):119–28. PubMed PMID: 20083042; PMCID: PMC2819840. DOI: 10.1016/S1474-4422(09)70299-6 [PubMed: 20083042]
25. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr. Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010; 74(3):201–9. Epub 2010/01/01. PubMed PMID: 20042704; PMCID: 2809036. DOI: 10.1212/WNL.0b013e3181cb3e25 [PubMed: 20042704]
26. Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis. 1980; 35(3):259–66. Epub 1980/03/01. doi: 0021-9150(80)90124-0 [pii]. PubMed PMID: 7362699. [PubMed: 7362699]
27. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003; 168(1):1–14. PubMed PMID: 12732381. [PubMed: 12732381]
28. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353–6. PubMed PMID: 12130773. DOI: 10.1126/science.1072994 [PubMed: 12130773]
29. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991; 349(6311):704–6. PubMed PMID: 1671712. DOI: 10.1038/349704a0 [PubMed: 1671712]
30. Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013; 12(10):957–65. Epub 2013/09/10. PubMed PMID: 24012374; PMCID: Pmc3904678. DOI: 10.1016/s1474-4422(13)70194-7 [PubMed: 24012374]
31. Lim YY, Maruff P, Pietrzak RH, Ellis KA, Darby D, Ames D, Harrington K, Martins RN, Masters CL, Szoek C, Savage G, Villemagne VL, Rowe CC. Abeta and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease. Alzheimers Dement. 2014; 10(6):743–51. e1. Epub 2014/03/05. PubMed PMID: 24589436. DOI: 10.1016/j.jalz.2013.11.005 [PubMed: 24589436]
32. Wang F, Gordon BA, Ryman DC, Ma S, Xiong C, Hassenstab J, Goate A, Fagan AM, Cairns NJ, Marcus DS, McDade E, Ringman JM, Graff-Radford NR, Ghetti B, Farlow MR, Sperling R, Salloway S, Schofield PR, Masters CL, Martins RN, Rossor MN, Jucker M, Danek A, Förster S, Lane CA, Morris JC, Benzinger TL, Bateman RJ, Network DIA. Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology. 2015; 85(9):790–8. PubMed PMID: 26245925. DOI: 10.1212/WNL.0000000000001903 [PubMed: 26245925]
33. Hassenstab, J.; Lim, Y.; Fagan, A.; Ma, S.; Xiong, C.; Bateman, R.; Morris, J.; Network atDIA. , editors. CSF Biomarkers and Cognitive Decline in Autosomal Dominant Alzheimer Disease. Alzheimer's Association International Conference; Washington, DC. 2015;
34. Maloney JA, Bainbridge T, Gustafson A, Zhang S, Kyauk R, Steiner P, van der Brug M, Liu Y, Ernst JA, Watts RJ, Atwal JK. Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. J Biol Chem. 2014; 289(45):30990–1000. PubMed PMID: 25253696; PMCID: PMC4223305. DOI: 10.1074/jbc.M114.589069 [PubMed: 25253696]

35. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K. Variant of TREM2 associated with the risk of Alzheimer's disease. *N Engl J Med*. 2013; 368(2):107–16. PubMed PMID: 23150908; PMCID: PMC3677583. DOI: 10.1056/NEJMoa1211103 [PubMed: 23150908]
36. Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. *J Neurosci*. 2010; 30(36):11938–50. PubMed PMID: 20826658. DOI: 10.1523/JNEUROSCI.2357-10.2010 [PubMed: 20826658]
37. Gomez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. *J Neurosci*. 1996; 16(14):4491–500. Epub 1996/07/15. PubMed PMID: 8699259. [PubMed: 8699259]
38. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. *Ann Neurol*. 1999; 45(3):358–68. Epub 1999/03/11. PubMed PMID: 10072051. [PubMed: 10072051]
39. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiol Aging*. 1995; 16(3):271–8. discussion 8-84. PubMed PMID: 7566337. [PubMed: 7566337]
40. Cray JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, Arnold SE, Attems J, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Gearing M, Grinberg LT, Hof PR, Hyman BT, Jellinger KA, Jicha GA, Kovacs GG, Knopman DS, Kofler J, Kukull WA, Mackenzie IR, Masliah E, McKee A, Montine TJ, Murray ME, Neltner JH, Santa-Maria I, Seeley WW, Serrano-Pozo A, Shelanski ML, Stein T, Takao M, Thal DR, Toledo JB, Troncoso JC, Vonsattel JP, White CL 3rd, Wisniewski T, Woltjer RL, Yamada M, Nelson PT. Primary age-related tauopathy (PART): a common pathology associated with human aging. *Acta Neuropathol*. 2014; 128(6):755–66. PubMed PMID: 25348064; PMCID: PMC4257842. DOI: 10.1007/s00401-014-1349-0 [PubMed: 25348064]
41. Thal DR, Papassotiropoulos A, Saido TC, Griffin WS, Mrak RE, Kolsch H, Del Tredici K, Attems J, Ghebremedhin E. Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer's disease. *Acta Neuropathol*. 2010; 120(2):169–83. Epub 2010/06/11. PubMed PMID: 20535486. DOI: 10.1007/s00401-010-0707-9 [PubMed: 20535486]
42. Shepherd C, McCann H, Halliday GM. Variations in the neuropathology of familial Alzheimer's disease. *Acta Neuropathol*. 2009; 118(1):37–52. PubMed PMID: 19306098. DOI: 10.1007/s00401-009-0521-4 [PubMed: 19306098]
43. Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, Joshi AD, Devous MD Sr, Mintun MS. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. *Brain*. 2016; 139(Pt 5):1539–50. Epub 2016/03/05. PubMed PMID: 26936940. DOI: 10.1093/brain/aww023 [PubMed: 26936940]
44. Benzinger TF, Su Y, Gordon B, Christensen J, Hornbeck R, Mishra S, Aldea P, Cash L, Ances B, McConathy J, Koeppe R, Cairns N, Morris J, Bateman R. Patterns of tau deposition using [18F]-AV-1451 in autosomal dominant Alzheimer's disease: Results from the DIAN. *Human Amyloid Imaging*. 2016; S7:125.
45. Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. *Neuron*. 2013; 80(6):1347–58. PubMed PMID: 24360540; PMCID: PMC3928967. DOI: 10.1016/j.neuron.2013.12.003 [PubMed: 24360540]
46. Benzinger TL, Blazey T, Jack CR, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, Cairns NJ, Fagan AM, Goate A, Marcus DS, Aisen PS, Christensen JJ, Ercole L, Hornbeck RC, Farrar AM, Aldea P, Jasielec MS, Owen CJ, Xie X, Mayeux R, Brickman A, McDade E, Klunk W, Mathis CA, Ringman J, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Salloway S, Correia S, Schofield PR, Masters CL, Rowe C, Villemagne VL, Martins R, Ourselin S, Rossor MN, Fox NC, Cash DM, Weiner MW, Holtzman DM, Buckles VD, Moulder K, Morris JC. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. *Proc Natl Acad Sci U S A*. 2013; 110(47):E4502–9. PubMed PMID: 24194552; PMCID: PMC3839740. DOI: 10.1073/pnas.1317918110 [PubMed: 24194552]

47. Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gutierrez Gomez M, Langois CM, Langbaum JB, Roontiva A, Thiyyagura P, Lee W, Ayutyanont N, Lopez L, Moreno S, Munoz C, Tirado V, Acosta-Baena N, Fagan AM, Giraldo M, Garcia G, Huentelman MJ, Tariot PN, Lopera F, Reiman EM. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. *JAMA Neurol.* 2015; 72(3):316–24. PubMed PMID: 25580592; PMCID: PMC4355261. DOI: 10.1001/jamaneurol.2014.3314 [PubMed: 25580592]
48. Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, Farlow M, Fox N, Ghetti B, Goate AM, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk WE, Marcus DS, Martins RN, Masters CM, Mayeux R, McDade E, Morris JC, Oliver A, Ringman JM, Rossor MN, Salloway S, Schofield PR, Snider J, Snyder P, Sperling RA, Stewart C, Thomas RG, Xiong C, Bateman RJ. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. *Rev Neurol (Paris).* 2013; 169(10):737–43. PubMed PMID: 24016464; PMCID: PMC3880800. DOI: 10.1016/j.neurol.2013.07.017 [PubMed: 24016464]
49. Moulder KL, Snider BJ, Mills SL, Buckles VD, Santacruz AM, Bateman RJ, Morris JC. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. *Alzheimer's research & therapy.* 2013; 5(5):48. Epub 2013/10/18. PubMed PMID: 24131566; PMCID: Pmc3978584. doi: 10.1186/alzrt213
50. Reiman EM, Langbaum JB, Tariot PN, Lopera F, Bateman RJ, Morris JC, Sperling RA, Aisen PS, Roses AD, Welsh-Bohmer KA, Carrillo MC, Weninger S. CAP-advancing the evaluation of preclinical Alzheimer disease treatments. *Nat Rev Neurol.* 2016; 12(1):56–61. PubMed PMID: 26416539. DOI: 10.1038/nrneurol.2015.177 [PubMed: 26416539]
51. Lim Y, Pietrzak R, Snyder P, Darby D, Maruff P. Preliminary data on the effect of culture on the assessment of Alzheimer's disease-related verbal memory impairment with the International Shopping List Test. *Arch Clin Neuropsychol.* 2012; 27:136–47. NIHMSID: PMID:22198565. [PubMed: 22198565]
52. Acevedo A, Krueger KR, Navarro E, Ortiz F, Manly JJ, Padilla-Velez MM, Weintraub S, Lopez OL, Mungas D. The Spanish translation and adaptation of the Uniform Data Set of the National Institute on Aging Alzheimer's Disease Centers. *Alzheimer Dis Assoc Disord.* 2009; 23(2):102–9. PubMed PMID: 19474568; PMCID: PMC2963171. DOI: 10.1097/WAD.0b013e318193e376 [PubMed: 19474568]
53. Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, Quiroz YT, Kosik KS, Lopera F, Tariot PN. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. *Journal of Alzheimer's disease : JAD.* 2011; 26(Suppl 3):321–9. PubMed PMID: 21971471; PMCID: 3343739. DOI: 10.3233/JAD-2011-0059 [PubMed: 21971471]
54. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, Fagan AM, Shah AR, Alvarez S, Arbelaez A, Giraldo M, Acosta-Baena N, Sperling RA, Dickerson B, Stern CE, Tirado V, Munoz C, Reiman RA, Huentelman MJ, Alexander GE, Langbaum JBS, Kosik KS, Tariot PN, Lopera F. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. *The Lancet Neurology.* 2012; 11(12):1048–56. [PubMed: 23137948]
55. Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. *Ann Neurol.* 2011; 70(2):274–85. PubMed PMID: 21823155; PMCID: PMC3154071. DOI: 10.1002/ana.22448 [PubMed: 21823155]
56. Tarawneh R, D'Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, Zipfel GJ, Ladenson JH, Morris JC, Holtzman DM. The diagnostic and prognostic utility of the synaptic marker, neurogranin, in Alzheimer's disease. *JAMA Neurol.* 2016 In press.
57. Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. *JAMA Neurol.* 2015; 72(11):1275–80. PubMed PMID: 26366630; PMCID: PMC4694558. DOI: 10.1001/jamaneurol.2015.1867 [PubMed: 26366630]

58. Kvartsberg H, Duits FH, Ingelsson M, Andreassen N, Ohrfelt A, Andersson K, Brinkmalm G, Lannfelt L, Minthon L, Hansson O, Andreasson U, Teunissen CE, Scheltens P, Van der Flier WM, Zetterberg H, Portelius E, Blennow K. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. *Alzheimers Dement*. 2014; PubMed PMID: 25533203. doi: 10.1016/j.jalz.2014.10.009
59. Brinkmalm A, Brinkmalm G, Honer WG, Frolich L, Hausner L, Minthon L, Hansson O, Wallin A, Zetterberg H, Blennow K, Ohrfelt A. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. *Mol Neurodegener*. 2014; 9:53. PubMed PMID: 25418885; PMCID: PMC4253625. doi: 10.1186/1750-1326-9-53 [PubMed: 25418885]
60. Skillback T, Farahmand B, Bartlett JW, Rosen C, Mattsson N, Nagga K, Kilander L, Religa D, Wimo A, Winblad B, Rosengren L, Schott JM, Blennow K, Eriksdotter M, Zetterberg H. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. *Neurology*. 2014; 83(21):1945–53. PubMed PMID: 25339208. DOI: 10.1212/WNL.0000000000001015 [PubMed: 25339208]
61. Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, Hansson O. Plasma tau levels in Alzheimer's disease. *Alzheimer's research & therapy*. 2013; 5(2):9. PubMed PMID: 23551972; PMCID: PMC3707015. doi: 10.1186/alzrt163
62. Blazey, T.; Jack, C.; Kantarci, K.; Preboske, G.; Ringman, J.; Brickman, A.; Raichle, M.; Hornbeck, R.; Saykin, A.; Salloway, S.; McDade, E.; Rossor, M.; Fox, N.; Thompson, P.; Correia, S.; Rowe, C.; Weiner, M.; Mayeux, R.; Ghetti, B.; Sperling, R.; Johnson, K.; Schofield, P.; Masters, C.; Martins, P.; Aisen, P.; Bateman, R.; Cairns, N.; Goate, A.; Marcus, D.; Fagan, A.; Xiong, C.; Buckles, V.; Moulder, K.; Morris, J.; Benzinger, T., editors. Prevalence and growth of cerebral microhemorrhages in autosomal dominant Alzheimer's disease. *Alzheimer's Association International Conference and Alzheimer's Imaging Consortium*; Boston, MA. July 13-18; 2013;
63. Wang X, Cusick MF, Wang Y, Sun P, Libbey JE, Trinkaus K, Fujinami RS, Song SK. Diffusion basis spectrum imaging detects and distinguishes coexisting subclinical inflammation, demyelination and axonal injury in experimental autoimmune encephalomyelitis mice. *NMR in biomedicine*. 2014; 27(7):843–52. Epub 2014/05/13. PubMed PMID: 24816651; PMCID: Pmc4071074. DOI: 10.1002/nbm.3129 [PubMed: 24816651]
64. Wang Y, Wang Q, Halder JP, Yeh FC, Xie M, Sun P, Tu TW, Trinkaus K, Klein RS, Cross AH, Song SK. Quantification of increased cellularity during inflammatory demyelination. *Brain*. 2011; 134(Pt 12):3590–601. PubMed PMID: 22171354; PMCID: PMC3235568. DOI: 10.1093/brain/awr307 [PubMed: 22171354]
65. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial I. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. *Neurology*. 2009; 73(24):2061–70. PubMed PMID: 19923550; PMCID: 2790221. DOI: 10.1212/WNL.0b013e3181c67808 [PubMed: 19923550]
66. Jacobsen H, Ozmen L, Caruso A, Narquizian R, Hilpert H, Jacobsen B, Terwel D, Tanghe A, Bohrmann B. Combined treatment with a BACE inhibitor and anti-Abeta antibody gantenerumab enhances amyloid reduction in APP^{London} mice. *J Neurosci*. 2014; 34(35):11621–30. Epub 2014/08/29. PubMed PMID: 25164658; PMCID: Pmc4145168. DOI: 10.1523/jneurosci.1405-14.2014 [PubMed: 25164658]
67. DeMattos, Rp; May, Pp; Racke, Mp; Hole, Jp; Tzaferis, Jp; Liu, Fp; DeLong, Cp; Day, Tp; Yang, Zp; Boggs, Lp; Monk, Sp; Mergott, Dp; Tang, Yp; Lu, Jp; Hutton, Mp; Nordstedt, Cp; Anderson, Wp; Iverson, Pp. Combination therapy with a plaque-specific abeta antibody and Bace inhibitor results in dramatic plaque lowering in aged PDAPP transgenic mice. *Alzheimer's & Dementia*. 2014; 10(4):149.
68. G S. Combination drug trials: time to open a new front in AD?. *AlzForum*. 2013.
69. G S. Combination trial debate energizes keystone symposium. *Keystone Symposium: Alzheimer's Disease - From fundamentals to light at the end of the translational tunnel: AlzForum*. 2014.
70. Stephenson D, Perry D, Bens C, Bain LJ, Berry D, Krams M, Sperling R, Diltz D, Luthman J, Hanna D, McKew J, Temple R, Fields FO, Salloway S, Katz R. Charting a path toward combination therapy for Alzheimer's disease. *Expert review of neurotherapeutics*. 2015; 15(1):

- 107–13. Epub 2014/12/30. PubMed PMID: 25540951. DOI: 10.1586/14737175.2015.995168 [PubMed: 25540951]
71. Perry D, Sperling R, Katz R, Berry D, Dilts D, Hanna D, Salloway S, Trojanowski JQ, Bountra C, Krams M, Luthman J, Potkin S, Gribkoff V, Temple R, Wang Y, Carrillo MC, Stephenson D, Snyder H, Liu E, Ware T, McKew J, Fields FO, Bain LJ, Bens C. Building a roadmap for developing combination therapies for Alzheimer's disease. Expert review of neurotherapeutics. 2015; 15(3):327–33. Epub 2015/02/25. PubMed PMID: 25708309. DOI: 10.1586/14737175.2015.996551 [PubMed: 25708309]
72. Grill JD, Bateman RJ, Buckles V, Oliver A, Morris JC, Masters CL, Klunk WE, Ringman JM. A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. Alzheimer's research & therapy. 2015; 7(1):50. Epub 2015/07/24. PubMed PMID: 26203303; PMCID: Pmc4511231. doi: 10.1186/s13195-015-0135-0
73. Association As. Changing the Trajectory of Alzheimer's Disease: How a Treatment by 2025 Saves Lives and Dollars. 2015.

Highlights

- We describe innovative trial design features of interest for AD adaptive or prevention trials
- DIAN observational study data were used to model ADAD cognitive decline
- The DIAN-TU cognitive composite is sensitive to early cognitive changes in ADAD
- The disease progression model significantly improves power over traditional analytical methods
- DIAN-TU NexGen trial will test therapeutics to prevent or slow cognitive decline due to ADAD

Research in Context

1. Systematic review: The authors reviewed articles and books pertaining to clinical trial design and held numerous in person and teleconference meetings with a variety of experts including clinicians, researchers, statisticians, patient advocates, and regulatory, clinical development, imaging and informatics professionals.
2. Interpretation: This article outlines innovative trial design features that may be implemented in the DIAN-TU NexGen trial and considered by others developing adaptive trials for Alzheimer's or related diseases. We developed a mathematical model for the DIAN observational study that provides a clear and consistent pattern of disease progression for ADAD mutation carriers; the model fit provides a powerful way to simulate future subjects in the DIAN-TU trial and significant improvements in power over traditional analytical methods.
3. Future directions: Launch of the DIAN-TU NexGen trial will enable testing of new therapeutics to determine if one or more is able to prevent or slow cognitive decline due to autosomal dominant AD.




Figure 1. Existing and proposed structure of the DIAN-TU trial platform including the Next Generation Prevention Trial. Pink indicates enrollment of the first two arms, pink and green the biomarker phase, and green denotes graduation to a cognitive endpoint. In this article we describe design considerations for the two NexGen arms including proposed interim analyses based on biomarkers and performance on the DIAN-TU cognitive composite.

DIAN-TU Trial and DIAN Observational Study Current and Possible Future Sites



Figure 2.
Current and possible future DIAN-TU and DIAN Observational study sites. The trial is active at 26 sites in 7 countries.

Cognitive Performance by Estimated Years to Onset




Figure 3. DIAN-TU Cognitive Composite performance by estimated year to symptom onset in Mutation Carriers (red, n=223) and Non-Carriers (black, n=142) from the DIAN Observational Study Data Freeze 9. The four components of the test include Logical Memory Delayed Recall, DIAN Word List Test (comparable to International Shopping List Test used in DIAN-TU), Digit Symbol Coding and MMSE.




Figure 4.

Longitudinal and Cross-Sectional Cognitive Performance in Mutation Carriers. Disease progression modeling demonstrating the dramatic improvement in variance for cognitive decline (right panel) after accounting for subject level EYO and subject level baseline cognitive performance.




Figure 5.

Proportional hypothetical treatment effects yield different absolute changes depending on EYO. The red line represents the natural (i.e. placebo) rate of cognitive decline across EYO. The colored lines illustrate different levels of slowing disease progression based on drug effect across EYO.